These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 35914259)

  • 1. In persons at risk for poor vaccination response or COVID-19 exposure, tixagevimab + cilgavimab reduced COVID-19.
    Aisenberg GM
    Ann Intern Med; 2022 Aug; 175(8):JC92. PubMed ID: 35914259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.
    Levin MJ; Ustianowski A; De Wit S; Launay O; Avila M; Templeton A; Yuan Y; Seegobin S; Ellery A; Levinson DJ; Ambery P; Arends RH; Beavon R; Dey K; Garbes P; Kelly EJ; Koh GCKW; Near KA; Padilla KW; Psachoulia K; Sharbaugh A; Streicher K; Pangalos MN; Esser MT;
    N Engl J Med; 2022 Jun; 386(23):2188-2200. PubMed ID: 35443106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial.
    Hobbs FDR; Montgomery H; Padilla F; Simón-Campos JA; Kim K; Arbetter D; Padilla KW; Reddy VP; Seegobin S; Streicher K; Templeton A; Viani RM; Johnsson E; Koh GCKW; Esser MT
    Infect Dis Ther; 2023 Sep; 12(9):2269-2287. PubMed ID: 37751015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19.
    Clegg LE; Stepanov O; Schmidt H; Tang W; Zhang H; Webber C; Cohen TS; Esser MT; Någård M
    Antimicrob Agents Chemother; 2024 May; 68(5):e0158723. PubMed ID: 38534112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.
    Levin MJ; Ustianowski A; Thomas S; Templeton A; Yuan Y; Seegobin S; Houlihan CF; Menendez-Perez I; Pollett S; Arends RH; Beavon R; Dey K; Garbes P; Kelly EJ; Koh GCKW; Ivanov S; Near KA; Sharbaugh A; Streicher K; Pangalos MN; Esser MT;
    Clin Infect Dis; 2023 Apr; 76(7):1247-1256. PubMed ID: 36411267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review.
    Ustianowski A
    Expert Rev Anti Infect Ther; 2022 Dec; 20(12):1517-1527. PubMed ID: 36217836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis.
    Glhoom S; Fergany A; El-Araby D; Abdelkhalek AA; Gomaa A; Zayed EO; Abd-ElGwad M
    Eur J Med Res; 2024 Jan; 29(1):27. PubMed ID: 38183123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants.
    Tuffy KM; Ahani B; Aksyuk AA; Avila M; Brady T; Kijak GH; Koh G; Levin MJ; Roe TL; Schuko N; Thissen J; Ustianowski A; Zhang T; Kelly EJ; Streicher K
    J Infect Dis; 2023 Oct; 228(8):1055-1059. PubMed ID: 37280116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial.
    Hites M; Massonnaud CR; Lapique EL; Belhadi D; Jamard S; Goehringer F; Danion F; Reignier J; de Castro N; Garot D; Lacombe K; Tolsma V; Faure E; Malvy D; Staub T; Courjon J; Cazenave-Roblot F; Dyrhol Riise AM; Leturnier P; Martin-Blondel G; Roger C; Akinosoglou K; Moing VL; Piroth L; Sellier P; Lescure X; Trøseid M; Clevenbergh P; Dalgard O; Gallien S; Gousseff M; Loubet P; Vardon-Bounes F; Visée C; Belkhir L; Botelho-Nevers É; Cabié A; Kotanidou A; Lanternier F; Rouveix-Nordon E; Silva S; Thiery G; Poignard P; Carcelain G; Diallo A; Mercier N; Terzic V; Bouscambert-Duchamp M; Gaymard A; Trabaud MA; Destras G; Josset L; Billard N; Han TH; Guedj J; Couffin-Cadiergues S; Dechanet A; Delmas C; Esperou H; Fougerou-Leurent C; Mestre SL; Métois A; Noret M; Bally I; Dergan-Dylon S; Tubiana S; Kalif O; Bergaud N; Leveau B; Eustace J; Greil R; Hajdu E; Halanova M; Paiva JA; Piekarska A; Rodriguez Baño J; Tonby K; Trojánek M; Tsiodras S; Unal S; Burdet C; Costagliola D; Yazdanpanah Y; Peiffer-Smadja N; Mentré F; Ader F;
    J Infect; 2024 Mar; 88(3):106120. PubMed ID: 38367705
    [No Abstract]   [Full Text] [Related]  

  • 10. Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies.
    Stuver R; Shah GL; Korde NS; Roeker LE; Mato AR; Batlevi CL; Chung DJ; Doddi S; Falchi L; Gyurkocza B; Hamilton A; Lin YH; Jakubowski AA; Joffe E; Landau HL; Lin RJ; Mailankody S; Palomba ML; Park JH; Perales MA; Ponce DM; Ramanathan LV; Salles GA; Scordo M; Seo SK; Shah UA; Stein EM; Straus D; Usmani SZ; Young JW; Zelenetz AD; Noy A; Vardhana SA
    Cancer Cell; 2022 Jun; 40(6):590-591. PubMed ID: 35598602
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies].
    Roppelt AA; Lebedkina MS; Chernov AA; Kruglova TS; Mukhina OA; Yukhnovskaya YD; Samedova FA; Mаrkina UA; Andrenova GV; Karaulov AV; Lysenko MA; Fomina DS
    Ter Arkh; 2023 Feb; 95(1):78-84. PubMed ID: 37167118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tixagevimab-Cilgavimab: COVID-19 Pre-Exposure Prophylaxis.
    Martin JC
    Clin J Oncol Nurs; 2022 Sep; 26(5):479-482. PubMed ID: 36108215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry.
    Marchesi F; Salmanton-García J; Buquicchio C; Itri F; Besson C; Dávila-Valls J; Martín-Pérez S; Fianchi L; Rahimli L; Tarantini G; Grifoni FI; Sciume M; Labrador J; Cordoba R; López-García A; Fracchiolla NS; Farina F; Ammatuna E; Cingolani A; García-Bordallo D; Gräfe SK; Bilgin YM; Dargenio M; González-López TJ; Guidetti A; Lahmer T; Lavilla-Rubira E; Méndez GA; Prezioso L; Schönlein M; Van Doesum J; Wolf D; Hersby DS; Magyari F; Van Praet J; Petzer V; Tascini C; Falces-Romero I; Glenthøj A; Cornely OA; Pagano L
    J Hematol Oncol; 2023 Apr; 16(1):32. PubMed ID: 37005697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Intramuscular Tixagevimab-Cilgavimab in Prevention of COVID-19 in Patients Who Are Immunocompromised.
    Moon R; Tien A; Chung J; Pinnelas R; Lee R; Hwang J; Brasfield F; Sahota A
    Perm J; 2023 Dec; 27(4):44-54. PubMed ID: 37718610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of tixagevimab-cilgavimab as pre-exposure prophylaxis for COVID-19: A systematic review and meta-analysis.
    Soeroto AY; Yanto TA; Kurniawan A; Hariyanto TI
    Rev Med Virol; 2023 Mar; 33(2):e2420. PubMed ID: 36617704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Canadian Perspective: Monoclonal Antibodies for Pre- and Post-Exposure Protection from COVID-19 in Vulnerable Patients with Hematological Malignancies.
    Owen C; Robinson S; Christofides A; Sehn LH
    Curr Oncol; 2022 May; 29(6):3940-3949. PubMed ID: 35735424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS-CoV-2 Infection.
    Bender Ignacio RA; Wohl DA; Arends R; Pilla Reddy V; Mu Y; Javan AC; Hughes MD; Eron JJ; Currier JS; Smith D; Chew KW; Gibbs M; Fletcher CV
    Clin Pharmacol Ther; 2022 Dec; 112(6):1207-1213. PubMed ID: 35797235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study.
    Jakimovski D; Eckert SP; Mirmosayyeb O; Thapa S; Pennington P; Hojnacki D; Weinstock-Guttman B
    Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial).
    Kijak GH; Ahani B; Arbetter D; Chuecos F; Gopalakrishnan V; Beloor J; Brady T; Nguyen A; Roe TL; Schuko N; Zhang T; Hobbs FDR; Padilla F; Kelly EJ; Montgomery H; Streicher K
    Infect Dis Ther; 2023 Dec; 12(12):2691-2707. PubMed ID: 37914983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between AZD7442 (Tixagevimab-Cilgavimab) Administration and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Hospitalization, and Mortality.
    Kertes J; Shapiro Ben David S; Engel-Zohar N; Rosen K; Hemo B; Kantor A; Adler L; Shamir Stein N; Mizrahi Reuveni M; Shahar A
    Clin Infect Dis; 2023 Feb; 76(3):e126-e132. PubMed ID: 35904210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.